Let's start with title of presentation: Two parts are salient: Reduced Cognitive Decline (MMSE), let's tart with this. Maintained Activities of Daily Living Score (ADCS-ADL) Plot of MMSE score for different groups of patient in Phase 2a up to 109 weeks, some just extrapolated: High Ascending patients: 2010, 2006, 1014 & 1009. (Data up to … Continue reading $AVXL Soon Data on 148 weeks of ANVEX 2-73 Dosing (10/26/2018)
The Press Release state basic facts in points: So: Q: Who are study participants? A: 20 patients in all cohorts. Discussion: When you are an engineer they tell you to check the quality of large population of parts by drawing at random sample size of at least 30 parts from given batch. I worked for … Continue reading How to Parse the July 25, 2018 Press Release, All About Phase2b/3.
The Criteria for Phase 2b/3 On July 25, 2018 AVXL has given genetic and performance criteria resulting from KEM analysis study of 26 patients still in the Phase 2b at 57 weeks for best improvement. I did not know which patients had the right genetic material but I knew that some of them had initial scores … Continue reading $AVXL Phase 2b/3 Spoiler Alert, or is it?
The Press Release said ...... Since I crunched the numbers only for MMSE scores I will stay with these however they are flawed. From November 2017 we have data for all the 26 patients in Phase 2a for ANAVEX 2-73. With two exceptions, all the patients with positive delta MMSE score are located in the … Continue reading $AVXL Preview of Phase 2b/3for ANVEX 2-73.
Parkinson's and Alzheimer I did some reading on Parkinson's on Wikipedia and was looking for common thread here with Alzheimer. Let's start with Alzheimer (AD). The cause is unknown. Weak genetic connection. Those who carry genes connected with AD have 10% probability to have the familial form of the disease (vs. sporadic (no genetic connection)). … Continue reading $AVXL Parkinson, Alzheimer and Homeostasis Claim on ANAVEX 2-73